Exited position

George Soros’s Teva Pharmaceutical Industries (TEVA) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Soros Fund ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2009Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares10.31MHighest verified quarter-end share count
Quarters reported14Verified quarters with shares above zero
What happened?

Soros Fund Management first reported Teva Pharmaceutical Industries in Q4 2009. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Soros Fund Management sold the entire position in Q3 2015, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2015
Sold the entire position−423.31K shares · No shares reported at quarter-end
Q2 2015
New position+423.31K shares · 423.31K shares reported
Filing context

Quarter-end price $59.10 · Estimated holding basis $59.10

Q3 2014
Sold 14.3% of the position−1.04M shares · 6.23M shares remained
Filing context

Quarter-end price $53.75 · Estimated holding basis $40.51

Q2 2014
Sold 29.5% of the position−3.04M shares · 7.27M shares remained
Filing context

Quarter-end price $52.42 · Estimated holding basis $40.51

Q1 2014
Bought 10.7% more+994.04K shares · 10.31M shares reported after the change
Filing context

Quarter-end price $52.84 · Estimated holding basis $40.51

Q4 2013
Bought 158.2% more+5.71M shares · 9.32M shares reported after the change
Filing context

Quarter-end price $40.08 · Estimated holding basis $39.19

Portfolio importance

How important was Teva Pharmaceutical Industries in Soros Fund Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.3%Q2 2015
Last reported rank#95of 247 reported positions
Peak portfolio weight5.8%Q1 2014
Best historical rank#1Q4 2013
At peak importanceQ1 2014
TEVA
5.8%
Largest holding
5.8%
Cross-investor discovery

Who else owns Teva Pharmaceutical Industries?

Also reported by 4 other tracked investors in their latest verified filings.

David EinhornDME Capital Management
TEVA2.5% of reported portfolio
Stanley DruckenmillerDuquesne Family Office
TEVA0.5% of reported portfolio
Ray DalioBridgewater Associates, LP
TEVA0.2% of reported portfolio
Explore Teva Pharmaceutical Industries across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$39.252026-09-15

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Soros Fund Management LLC’s Form 13F disclosures—not George Soros’s personal brokerage account. George Soros founded the firm; its current CEO and chief investment officer is Dawn Fitzpatrick. Form 13F does not reveal exact trade dates, execution prices or the purpose of an option position.